Search

Your search keyword '"Mark Oette"' showing total 3 results
Start Over Author "Mark Oette" Journal hiv medicine
3 results on '"Mark Oette"'

1. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study

Author

Björn-Erik Ole Jensen, Daniel Gillor, Christoph Wyen, Mark Oette, Stefan Esser, Albrecht Stoehr, Christian Hoffmann, Ivanka Krznaric, Jan Thoden, Marcus Hentrich, Georg M. N. Behrens, M Hensel, Gerd Fätkenheuer, J van Lunzen, and Markus Müller

Subjects
Oncology, medicine.medical_specialty, business.industry, Health Policy, Incidence (epidemiology), medicine.disease, AIDS-related lymphoma, Lymphoma, Infectious Diseases, Immune system, immune system diseases, hemic and lymphatic diseases, Internal medicine, Immunology, Medicine, Pharmacology (medical), Viral suppression, business, Prospective cohort study, Viral load, Cohort study
Abstract

Objectives The incidence of HIV-related non-Hodgkin lymphoma (NHL) but not that of Hodgkin lymphoma (HL) has been declining. The aim of the study was to compare HIV-infected patients with NHL and HL with respect to antiretroviral therapy (ART) exposure at the time of lymphoma diagnosis. Methods HIV-infected patients with NHL and HL included in a prospective multicentre cohort study since January 2005 were compared with respect to ART exposure and viral load at the time of lymphoma diagnosis. Results As of 31 December 2012, data for 329 patients with NHL and 86 patients with HL from 31 participating centres were available. Patients with HL were more likely to be on ART (73.5% vs. 39.1%, respectively; P 12 months and a CD4 cell count of > 200 cells/μL. Of note, 45.8% of all patients with NHL were not currently on ART and had a CD4 count of

Published
2014

2. Haemodynamic crisis and reversible multiorgan failure caused by HIV post-exposure prophylaxis after needle-stick injury in a health care worker

Author

A Kroidl, K Goebels, Dieter Häussinger, M Wenning, Mark Oette, and Torsten Feldt

Subjects
medicine.medical_specialty, Infectious Disease Transmission, Patient-to-Professional, Multiple Organ Failure, Nurses, Hemodynamics, HIV Infections, macromolecular substances, Zidovudine, Antiretroviral Therapy, Highly Active, Occupational Exposure, Health care, medicine, Humans, Drug Interactions, Pharmacology (medical), Needlestick Injuries, Intensive care medicine, Adverse effect, business.industry, Health Policy, virus diseases, Lamivudine, Lopinavir, Middle Aged, Infectious Diseases, Diabetes Mellitus, Type 2, Concomitant, Female, Ritonavir, business, medicine.drug
Abstract

We report the case of a 59-year-old nurse from our HIV ward who developed a severe haemodynamic crisis with concomitant acute multiorgan failure after initiation of a post-exposure prophylaxis (PEP) with zidovudine/lamivudine (CombivirTM) and lopinavir/ritonavir (KaletraTM) after a needle-stick injury with an HIV-contaminated needle. Although serious and life-threatening adverse effects of post-exposure prophylaxis have been documented in several cases, this is the first report of a severe acute cardiovascular incident following PEP initiation.

Published
2004

3. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy

Author

Hans-Dieter Nischalke, Bergmann F, Juergen K. Rockstroh, H Knechten, Gerd Fätkenheuer, Mathias Lichterfeld, Jan-Christian Wasmuth, Carls H, Theisen A, Monica J. S. Nadler, Rieke A, W. Wiesel, Mark Oette, and S. Fenske

Subjects
Adult, CD4-Positive T-Lymphocytes, Male, medicine.medical_specialty, HIV Infections, Indinavir, Pharmacology, CD8-Positive T-Lymphocytes, Gastroenterology, Zidovudine, Internal medicine, medicine, Humans, Pharmacology (medical), Didanosine, Retrospective Studies, Ritonavir, business.industry, Health Policy, Stavudine, Lamivudine, HIV Protease Inhibitors, Middle Aged, Viral Load, Flow Cytometry, Infectious Diseases, Tolerability, HIV-1, RNA, Viral, Reverse Transcriptase Inhibitors, Drug Therapy, Combination, Female, business, Viral load, medicine.drug
Abstract

Objective To determine the long-term antiretroviral efficacy and tolerability of dual protease inhibitor (PI) therapy with indinavir (IDV)/ritonavir (RTV) at 400/400 mg twice a day (BID) in combination with two nucleoside reverse trancriptase inhibitors (NRTIs). Design and methods In an open-label, uncontrolled multicentre clinical trial, antiretroviral therapy naive patients (n = 93) with a high median baseline HIV-1 RNA level of 210 000 copies/mL (range 17 000–2 943 000) and a median CD4 cell count of 195 copies/µL (range 4–656 copies/µL) were started on a regimen of either zidovudine (ZDV)/lamivudine (3TC) (49%), stavudine (d4T)/3TC (38%) or d4T/didanosine (ddI) (14%) plus RTV and IDV, each at 400 mg BID. CD4 cell counts and HIV RNA were determined at 4-week intervals for a duration of 72 weeks. Statistical analysis was performed on treatment as well as by intent to treat, where missing values were counted as failures. Results HIV RNA levels below the limit of detection were achieved in 59.5% (

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results